Vanguard Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$148M Buy
5,077,511
+853,287
+20% +$22.6M ﹤0.01% 1290
2026
Q2
$75.9M Buy
4,224,224
+82,649
+2% +$1.28M ﹤0.01% 1709
2026
Q1
$57.6M Buy
+4,141,575
New +$58.3M ﹤0.01% 1791

Other funds holding AMLX

Vanguard Capital Management's AMLX Position: Q3 2026 in Review

Vanguard Capital Management increased its Amylyx Pharmaceuticals (AMLX) stake by 20% in Q3 2026, buying an estimated $22.6M and bringing the position to 5,077,511 shares worth $148M. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Vanguard Capital Management first reported a position in AMLX in Q1 2026 and has held it in 3 quarters since. 230 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • Vanguard Capital Management held 5,077,511 shares of Amylyx Pharmaceuticals worth $148M as of Q3 2026.
  • Vanguard Capital Management bought 853,287 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $22.6M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1290 holding.
  • Vanguard Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 230 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.